Hyperglycemia
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In this study, fecal microbiota transplantation (FMT) using fecal material from metformin-treated mice was found to upregulate the expression of GLP-1 and pattern-recognition receptors TLR1 and TLR4 for the improvement in hyperglycemia caused by a high-fat diet.
|
31501716 |
2019 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Although glucagon-like peptide 1- (GLP-1-) based therapy of hyperglycemia in burn injury has shown great potential in clinical trials, its safety is seldom evaluated.
|
30800001 |
2019 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
These characteristics make GLP-1 receptor agonists attractive agents to treat dysglycaemia in perioperative or high-dependency hospital settings, where glycaemic variability and hyperglycaemia are associated with poor prognosis.
|
31141838 |
2019 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
GLP-1 antagonist significantly blocked the inhibitory effect of IES on hyperglycemia from 15 to 120 min (all p < 0.05).
|
30728346 |
2019 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Single-cell digital PCR revealed GLP-1 receptor expression in neurogliaform cells and showed that copy numbers of mRNA of the Glp1r gene in hyperglycaemia exceeded those in hypoglycaemia by 9.6 times (p < 0.008).
|
30637442 |
2019 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
We hypothesized that the downregulation of GLP-1R by hyperglycemia might reduce the renal-protective effects of GLP-1R agonists in diabetic nephropathy (DN).
|
31136032 |
2019 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptors are involved in the liraglutide-induced relaxation of branched arteries, under normoglycaemic conditions, while GLP-1 inhibition of vascular superoxide levels contributes to GLP-1 receptor-independent potentiation of endothelium-dependent vasodilatation in hyperglycaemia.
|
30403290 |
2019 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Treatment with an N2 supplement in combination with three soluble factors (glucagon-like peptide-1 [GLP-1] receptor agonist, notch inhibitor, and transforming growth factor-β [TGF-β] inhibitor) enhanced liver-to-pancreas transdifferentiation based on the following findings: i) the incidence of c-peptide-positive cells increased by approximately 1.2-fold after the aforementioned treatment; ii) the c-peptide expression level in the treated cells increased by approximately 12-fold as compared with the level in the untreated cells; iii) the treated cells secreted insulin in a glucose-dependent manner, whereas the untreated cells did not; and iv) transplantation of treated-transdifferentiated cells into streptozotocin-induced immunodeficient diabetic mice led to the amelioration of hyperglycemia.
|
29768476 |
2018 |
Hyperglycemia
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Sitagliptin, a dipeptidyl peptidase-IV inhibitor (DPP-4), sustains activity of the incretin hormones GLP-1 and GIP and improves hyperglycemia in Type 2 diabetes mellitus (T2DM).
|
29138226 |
2018 |
Hyperglycemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
There is no evidence that the GLP-1R agonists cause a major reduction in HbA1c, or have a major effect on hypo- or hyperglycemia in subjects with TD1M.
|
30234389 |
2018 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
There have been several new treatment approaches established for the management of hyperglycemia in type 2 diabetes (T2D), with treatment guidelines listing both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and basal insulin therapies as considerations for patients who have failed to control their blood glucose with oral antidiabetic agents.
|
29492243 |
2018 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results identify D-allulose as prominent GLP-1 releaser that acts via vagal afferents to restrict feeding and hyperglycemia.
|
29317623 |
2018 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucagonlike peptide 1 (GLP-1) receptor agonists have been efficacious for the treatment of type 2 diabetes due to their ability to reduce weight and attenuate hyperglycemia.
|
29905825 |
2018 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 (GLP-1)-based therapy via G protein-coupled receptor (GPCR) GLP-1R, to attenuate hyperglycemia in critical care has attracted great attention.
|
29022064 |
2018 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
We analyzed the impact of PARP-1 inhibition on <i>C. elegans</i> health in the setting of hyperglycemia and on glucose-stimulated GLP-1 secretion in human intestinal cells.
|
29392078 |
2018 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Based on our previous finding that GLP-1 could control hyperglycemia by increasing insulin secretion and inhibiting β-cell apoptosis in severe scald injuries, this study further confirmed that Exendin-4 could increase glycemic control following severe scald by preserving the histology of β cells in pancreatic islets and inhibiting their apoptosis.
|
30211851 |
2018 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
In clinical practice, they are also classified as basal or prandial GLP-1 receptor agonists to differentiate between patients who would benefit more from one or another based on characteristics such as previous treatment and the predominance of fasting or postprandial hyperglycemia.
|
28115994 |
2017 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Moreover, ursolic acid is more effective than betulinic acid in reduction of hyperglycemia and increase of GLP-1 secretion.
|
28756460 |
2017 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
In view of the predisposition of patients with chronic hyperglycaemia to glucagon-like peptide 1 receptor (GLP-1R) downregulation and the lag time to optimal efficacy of GLP-1R agonists, we propose that patients should have C-peptide levels measured to determine the risk of ketosis and whether insulin should be continued with dose adjustments when starting a GLP-1R agonist.
|
28710307 |
2017 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance.
|
28683295 |
2017 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
The observation that the insulinotropic actions of GLP-1 are reduced in type 2 diabetes mellitus (T2DM) led to the development of incretin-based therapies - GLP-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors - for the treatment of hyperglycaemia in these patients.
|
28869249 |
2017 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are injectable agents used for the treatment of hyperglycemia in type 2 diabetes.
|
28274140 |
2017 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
[6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic β-cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hyperglycemia in Lepr<sup>db/db</sup> type 2 diabetic mice.
|
28793909 |
2017 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
The implications of these findings are very important for the management of type 2 diabetes given that GLP-1 receptor agonist are currently approved for the treatment of hyperglycemia and glucagon receptor antagonists and GLP-1/glucagon dual agonists are under development.
|
28463898 |
2017 |
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
As the reductions in glycated haemoglobin and systolic blood pressure (SBP) in these trials were modest, and both trials lasted only a short period of time, reductions in hyperglycaemia and SBP are unlikely to be involved in the beneficial CV effects of GLP-1 receptor agonists.
|
28431669 |
2017 |